뇌 바이오마커 시장 : 바이오마커 유형, 검체 유형, 기술, 임상 적응증, 용도, 최종 사용자별 - 세계 예측(2026-2032년)

The Brain Biomarkers Market is projected to grow by USD 39.55 billion at a CAGR of 18.07% by 2032.

Brain Biomarkers Executive Summary for Diagnostic Providers

Brain biomarkers are moving from specialist research tools into routine clinical decision-making for neurodegenerative disease diagnostics, traumatic brain injury assessment, psychiatric research, and therapy monitoring. The field spans cerebrospinal fluid biomarkers, blood-based biomarkers, neuroimaging biomarkers, electrophysiology, genomics, proteomics, metabolomics, and digital biomarkers captured through wearables and connected devices.

The World Health Organization reports more than 55 million people living with dementia worldwide and nearly 10 million new cases each year, while neurological conditions affect more than 3 billion people globally. For diagnostic providers, this creates a clear opportunity to build validated, scalable, and clinically interpretable brain biomarker workflows that support earlier detection, differential diagnosis, patient stratification, and longitudinal disease monitoring.

Transformative Shifts in the Brain Biomarkers Landscape

The brain biomarkers landscape is shifting toward earlier detection, less invasive sampling, and biomarker-confirmed patient stratification. FDA approvals of anti-amyloid therapies such as lecanemab in 2023 and donanemab in 2024 have increased the need for amyloid and tau confirmation before treatment decisions, strengthening demand for PET imaging, CSF testing, and validated blood-based assays.

Clinical adoption is also changing as neurology moves from symptom-led diagnosis to biology-led assessment. The 2024 Alzheimer's Association criteria emphasize biomarker evidence, while hospitals and reference laboratories are investing in standardized pre-analytics, longitudinal monitoring, and integrated reports that combine biomarker results with cognitive, imaging, genetic, and clinical context. This shift is also raising expectations for quality control, cut-off harmonization, clinician education, and equitable access to advanced neurological diagnostics.

Cumulative Impact of Artificial Intelligence on Brain Biomarkers

Artificial intelligence is accelerating brain biomarker interpretation by improving image quantification, pattern recognition, and multimodal risk modeling. FDA public listings show rapid growth in authorized AI and machine learning-enabled medical devices, with medical imaging representing the largest category and neurology-related applications expanding.

For diagnostic providers, AI can reduce reader variability in MRI and PET analysis, support automated segmentation of brain structures, and integrate blood, CSF, genetic, electrophysiology, and digital data into clinically useful probability scores. However, adoption must be anchored in transparent validation, demographic bias assessment, cybersecurity controls, data provenance, explainability, and clinician oversight to meet laboratory, hospital, payer, and regulator expectations.

Key Regional Insights for Brain Biomarkers

North America leads clinical implementation because the United States combines advanced neurology networks, FDA-cleared diagnostic pathways, National Institutes of Health-backed research, large Alzheimer's disease cohorts, and payer frameworks tied to evidence generation. Canada supports adoption through public research institutions, memory clinics, and provincial health systems, although reimbursement pathways, test availability, and access to advanced imaging vary by jurisdiction.

Europe benefits from coordinated dementia strategies, strong academic consortia, and European Union regulation that is raising evidence expectations for in vitro diagnostics. The region is strengthening standardization for CSF, blood-based, and imaging biomarkers, while differences in national reimbursement and laboratory infrastructure continue to shape adoption. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia invest in aging-related healthcare capacity, hospital-based neurology, imaging infrastructure, precision medicine, and digital health, supported by rapidly growing demand linked to population aging and neurological disease burden. Latin America is advancing through private diagnostic networks, academic neurology centers, and rising dementia awareness, with Brazil and Mexico serving as important access hubs. The Middle East is increasing investment in specialty care, genomics, advanced imaging, and medical tourism, particularly through high-income health systems. Africa shows growing clinical need for brain biomarker-enabled diagnosis, but adoption is constrained by specialist shortages, affordability, laboratory capacity, and limited access to PET tracers, advanced MRI, and standardized biomarker testing.

Key Group Insights for Brain Biomarkers

The G7 remains central to brain biomarker innovation because the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom host leading pharmaceutical sponsors, dementia cohorts, diagnostic developers, academic medical centers, and regulatory systems that influence global evidence standards. The European Union is important for harmonized evidence generation under the In Vitro Diagnostic Regulation and for cross-border research programs that support assay validation, real-world evidence, data interoperability, and clinical guideline development.

BRICS countries are increasingly relevant as China, India, Brazil, Russia, and South Africa expand neurology care, hospital infrastructure, medical research participation, and clinical trial activity, although access remains uneven across urban and rural populations. ASEAN markets are improving diagnostic access through urban hospital systems, expanding private healthcare, and growing digital health adoption, while the GCC is investing in specialty care, genomics, advanced imaging, and medical tourism to support precision neurology. NATO markets overlap with many high-income health systems where secure health data infrastructure, defense-linked traumatic brain injury research, and advanced rehabilitation programs support biomarker development and implementation.

Key Country Insights for Brain Biomarkers

The United States is the most influential country market because FDA decisions, CMS coverage policies, National Institutes of Health funding, Veterans Health Administration research, and large Alzheimer's disease cohorts shape global standards for biomarker-confirmed diagnosis and therapy monitoring. Canada emphasizes research-driven adoption through academic hospitals and provincial systems, while Mexico and Brazil represent growing Latin American access markets with rising dementia awareness, expanding private diagnostics, and increasing demand for neurologist-supported testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong neurology centers with increasing demand for biomarker-confirmed diagnosis, especially in Alzheimer's disease, Parkinsonian syndromes, multiple sclerosis, and rare neurological conditions. Germany and France benefit from advanced hospital infrastructure and specialist networks, the United Kingdom supports implementation through research-led memory services and health technology evaluation, and Italy and Spain show growing use of imaging and laboratory-based neurological diagnostics. Russia remains shaped by uneven access, local regulatory dynamics, and regional differences in specialist availability.

Across Asia-Pacific, China is scaling neuroscience research, hospital capacity, and precision medicine programs; India offers high-volume unmet need driven by population scale and expanding private healthcare; Japan has strong aging-related demand and established neurological care pathways; South Korea supports technology-led diagnostics, digital health, and hospital-based innovation; and Australia combines clinical research strength with organized specialist networks and public health attention to dementia and brain health.

Actionable Recommendations for Brain Biomarker Leaders

Industry leaders should prioritize clinically validated assays, standardized sample handling, and clear interpretation frameworks that help neurologists act on results. Laboratories should align brain biomarker menus with high-impact use cases such as Alzheimer's disease, Parkinsonian syndromes, multiple sclerosis, traumatic brain injury, neuroinflammation, and therapy monitoring.

Vendors should build partnerships with academic memory clinics, imaging centers, AI developers, biobanks, and pharmaceutical sponsors. The strongest commercial strategies will combine analytical validity, clinical validity, health-economic evidence, payer engagement, diverse cohort validation, privacy-by-design data governance, and interoperable reporting that fits electronic health record workflows. Leaders should also invest in clinician education, reflex testing protocols, external quality assessment, and real-world evidence programs to support adoption across hospitals, reference laboratories, and specialty neurology practices.

Research Methodology for Brain Biomarker Analysis

This executive summary is grounded in secondary research from public health agencies, regulatory databases, peer-reviewed neurology literature, clinical guideline updates, and publicly available institutional disclosures. Sources considered include the World Health Organization, U.S. FDA, CMS, NIH, Alzheimer's Association, and major international neurology publications.

The methodology emphasizes verified disease-burden data, regulatory milestones, technology adoption evidence, clinical guideline direction, and regional healthcare infrastructure indicators. Insights were synthesized to support executive decision-making while avoiding unsupported market-size claims, promotional language, company references, or unverified performance comparisons. Regional and country narratives were developed by triangulating public health burden, regulatory readiness, specialty care capacity, imaging and laboratory access, and the maturity of precision neurology infrastructure.

Conclusion on the Brain Biomarkers Opportunity

Brain biomarkers are becoming essential to precision neurology as treatment selection, diagnosis, and monitoring increasingly require biological confirmation. The commercial and clinical opportunity is strongest where diagnostic accuracy, clinical workflow integration, reimbursement evidence, and scalable laboratory operations converge.

Diagnostic providers that invest now in validated blood, CSF, imaging, electrophysiology, genetic, and digital biomarker capabilities can strengthen their role in the next generation of neurological care. Success will depend on quality systems, standardized pre-analytics, AI governance, secure data integration, clinician trust, and evidence that demonstrates better decision-making for patients and health systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Brain Biomarkers Market, by Biomarker Type

• 7.1. Imaging Biomarkers
  • 7.1.1. MRI Biomarkers
  • 7.1.2. Nuclear Imaging Biomarkers
  • 7.1.3. CT-Based Biomarkers
• 7.2. Molecular Biomarkers
  • 7.2.1. Genomic Biomarkers
  • 7.2.2. Proteomic Biomarkers
  • 7.2.3. Metabolomic Biomarkers
  • 7.2.4. Lipidomic Biomarkers
  • 7.2.5. Transcriptomic Biomarkers
• 7.3. Electrophysiological Biomarkers
  • 7.3.1. Electroencephalography Biomarkers
  • 7.3.2. Magnetoencephalography Biomarkers
  • 7.3.3. Evoked Potential Biomarkers
• 7.4. Digital Biomarkers
  • 7.4.1. Wearable-Derived Biomarkers
  • 7.4.2. Smartphone-Based Biomarkers
  • 7.4.3. Digital Phenotyping Biomarkers

8. Brain Biomarkers Market, by Sample Type

• 8.1. Blood
  • 8.1.1. Plasma
  • 8.1.2. Serum
• 8.2. Cerebrospinal Fluid
• 8.3. Saliva
• 8.4. Urine
• 8.5. Brain Tissue

9. Brain Biomarkers Market, by Technology

• 9.1. Magnetic Resonance Imaging
• 9.2. Positron Emission Tomography
• 9.3. Computed Tomography
• 9.4. Next-Generation Sequencing
• 9.5. Electroencephalography
• 9.6. Mass Spectrometry
• 9.7. Microarray

10. Brain Biomarkers Market, by Clinical Indication

• 10.1. Neurodegenerative Disorders
• 10.2. Psychiatric Disorders
• 10.3. Neurodevelopmental Disorders
• 10.4. Traumatic Brain Injury
• 10.5. Stroke & Cerebrovascular Disorders
• 10.6. Brain Tumors
• 10.7. Neuroinflammatory & Demyelinating Disorders
• 10.8. Central Nervous System Infections
• 10.9. Epilepsy & Seizure Disorders

11. Brain Biomarkers Market, by Application

• 11.1. Screening & Risk Assessment
• 11.2. Diagnosis
• 11.3. Prognosis
• 11.4. Treatment Response Monitoring
• 11.5. Drug Discovery & Clinical Research

12. Brain Biomarkers Market, by End User

• 12.1. Contract Research Organizations
• 12.2. Diagnostic Laboratories & Imaging Centers
• 12.3. Hospitals
• 12.4. Pharmaceutical & Biotechnology Companies
• 12.5. Academic & Research Institutes
• 12.6. Specialty Neurology & Psychiatry Clinics
• 12.7. Government & Public Health Institutions

13. Brain Biomarkers Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Brain Biomarkers Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Brain Biomarkers Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. F. Hoffmann-La Roche Ltd
• 17.3. Thermo Fisher Scientific Inc.
• 17.4. Siemens Healthineers AG
• 17.5. Revvity, Inc.
• 17.6. GE HealthCare Technologies Inc.
• 17.7. Illumina, Inc.
• 17.8. Koninklijke Philips N.V.
• 17.9. Merck KGaA
• 17.10. DiaSorin S.p.A.
• 17.11. Danaher Corporation
• 17.12. QIAGEN N.V.
• 17.13. Bio-Rad Laboratories, Inc.
• 17.14. Bio-Techne Corporation
• 17.15. Fujirebio Inc.
• 17.16. Biogen, Inc.
• 17.17. Altoida
• 17.18. ANT Neuro
• 17.19. BioSensics, LLC
• 17.20. BrainScope Company Inc
• 17.21. Bruker Corporation
• 17.22. C2N Diagnostics
• 17.23. Cortechs.ai
• 17.24. EMOTIV
• 17.25. g.tec medical engineering GmbH
• 17.26. Hologic, Inc.
• 17.27. IXICO plc
• 17.28. Lantheus Holdings, Inc.
• 17.29. Linus Health
• 17.30. Myriad Genetics, Inc.
• 17.31. Neurotrack Technologies, Inc.
• 17.32. Quanterix Corporation
• 17.33. Quibim, S.L.
• 17.34. RUNE LABS, INC.
• 17.35. Synaptive Medical Inc.